Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
AbCellera is seeking a creative, experienced leader to shape the CMC strategy for late-stage antibody programs and to build a high-performing MSAT team in Vancouver, Canada.
You will transition lead assets from clinical manufacturing to commercial readiness, drive cross-functional collaboration with Regulatory, QA, and Supply Chain, and oversee tech transfers with CDMOs to ensure timely regulatory submissions and robust processes.
Each of us cares about someone who will need medicines. That’s why our vision is to repeatedly beat the odds to deliver breakthrough medicines to patients who need them. We pursue truth and scientific rigour and have the courage to work at the edge of the unknown.
We are looking for a creative, experienced and highly technical leader to shape the CMC strategy of our late-stage development programs through to commercialization. This is a rare opportunity to build and lead a late-stage Manufacturing Science and Technology (MSAT) function for high-impact antibody-based biologics. You will transition our lead asset from clinical manufacturing into a robust, commercially viable process and manage our late-stage CMC portfolio of combination products as our pipeline progresses through development.
AbCellera’s hiring range for this role is currently under review. Your base salary will be commensurate with your education and job-related knowledge, skills, and experience. In addition to base salary, we offer equity, annual bonus dependent on team and company performance, and a 6% (non-match) RRSP contribution.
You will have a CAD $1,500 annual Active Lifestyle Allowance, annual vacation, professional development opportunities, and comprehensive health benefits. And you’ll find a strong sense of community and connections across AbCellera through our work, clubs, and socials.
Creating medicines is the most important work we can do.
We are a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. We have built a platform for advancing antibody drug programs from target to clinic, and we are using it to build our internal pipeline.
Today, our pipeline includes two drug candidates in clinical development, two preclinical development candidates (DCs) in Investigational New Drug (IND)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
We believe that when tenacious people share a vision and work together, they can truly have a positive impact. That’s why we hire for character and intelligence, not just for CVs or experience.
We look for people with drive and energy. People we trust. People who need to know their days are being well spent. That their work really matters. In the end, our success will be measured by the impact of our medicines.